^
    Apply
    Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms (NCT06078930)
    Phase N/A
    Zhejiang Cancer Hospital
    Recruiting
    Last update posted :
    10/12/2023
    Initiation :
    04/06/2021
    Primary completion :
    01/01/2025
    Completion :
    12/31/2026
    HER-2
    |
    HER-2 expression
    Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma (NCT01268579)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    10/02/2023
    Initiation :
    12/28/2010
    Primary completion :
    10/31/2022
    Completion :
    10/31/2022
    EGFR • CDKN1A
    Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene (NCT03602079)
    Phase 1/2
    Klus Pharma Inc.
    Completed
    Last update posted :
    08/03/2023
    Initiation :
    07/16/2018
    Primary completion :
    01/12/2022
    Completion :
    01/12/2022
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    trastuzumab botidotin (A166)
    Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy (NCT01332279)
    Phase 1
    Fox Chase Cancer Center
    Withdrawn
    Last update posted :
    04/04/2023
    Initiation :
    04/01/2011
    Primary completion :
    05/01/2011
    Completion :
    05/01/2011
    EGFR • HIF1A
    |
    EGFR amplification • HIF1A expression • AKT1 amplification
    |
    erlotinib • everolimus
    Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (NCT02295540)
    Phase N/A
    Rutgers, The State University of New Jersey
    Withdrawn
    Last update posted :
    09/28/2022
    Initiation :
    08/01/2016
    Primary completion :
    01/01/2020
    Completion :
    01/01/2020
    CD4
    Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line (NCT05456022)
    Phase 2
    Cairo University
    Not yet recruiting
    Last update posted :
    07/13/2022
    Initiation :
    07/01/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    BCL2 • BAX • GAPDH • ANXA5
    |
    BCL2 expression • BAX expression
    Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study (ERLO-XIB) (NCT02748707)
    Phase 2
    Tata Memorial Hospital
    Active, not recruiting
    Last update posted :
    04/28/2022
    Initiation :
    08/18/2015
    Primary completion :
    02/12/2018
    Completion :
    04/01/2023
    EGFR • TP53
    |
    erlotinib • celecoxib oral
    PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT01816984)
    Phase 1/2
    University of Chicago
    Completed
    Last update posted :
    10/05/2021
    Initiation :
    05/01/2013
    Primary completion :
    04/01/2018
    Completion :
    09/01/2020
    EGFR
    |
    Erbitux (cetuximab) • cisplatin • buparlisib (AN2025)
    GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer (NCT00293462)
    Phase 3
    Marilyn Dodd
    Completed
    Last update posted :
    07/30/2021
    Initiation :
    06/07/2005
    Primary completion :
    12/31/2009
    Completion :
    12/31/2009
    CSF2
    |
    Leukine (sargramostim)
    Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (NCT01254617)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/13/2020
    Initiation :
    02/10/2011
    Primary completion :
    01/29/2014
    Completion :
    01/29/2014
    EGFR • KRAS
    |
    KRAS wild-type • RAS wild-type
    |
    Erbitux (cetuximab) • lenalidomide • Datalai (cetuximab biosimilar)
    Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (NCT01316757)
    Phase 2
    Fox Chase Cancer Center
    Completed
    Last update posted :
    02/26/2018
    Initiation :
    02/16/2011
    Primary completion :
    04/07/2015
    Completion :
    10/03/2017
    EGFR
    |
    Erbitux (cetuximab) • erlotinib • carboplatin • paclitaxel
    Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab (NCT00939627)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/23/2018
    Initiation :
    07/01/2009
    Primary completion :
    01/01/2013
    Completion :
    01/01/2014
    TGFB1
    |
    Erbitux (cetuximab) • sorafenib
    Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (NCT00407810)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/20/2017
    Initiation :
    10/01/2006
    Primary completion :
    02/01/2012
    EGFR
    |
    Avastin (bevacizumab) • Erbitux (cetuximab)
    Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line (NCT03288298)
    Phase 1
    Cairo University
    Unknown status
    Last update posted :
    09/20/2017
    Initiation :
    11/01/2017
    Primary completion :
    09/01/2018
    Completion :
    04/01/2019
    CASP3
    Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery (NCT02007200)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/24/2016
    Initiation :
    07/01/2009
    Primary completion :
    09/01/2015
    Completion :
    09/01/2015
    IL6